Search hospitals

>

California

>

Los Angeles

University of Southern California

Claim this profile

Los Angeles, California 90033

Global Leader in Cancer

Global Leader in Alzheimer's Disease

Conducts research for HIV Infection

Conducts research for Lung Cancer

Conducts research for Pancreatic Cancer

660 reported clinical trials

61 medical researchers

Photo of University of Southern California in Los AngelesPhoto of University of Southern California in Los Angeles

Summary

University of Southern California is a medical facility located in Los Angeles, California. This center is recognized for care of Cancer, Alzheimer's Disease, HIV Infection, Lung Cancer, Pancreatic Cancer and other specialties. University of Southern California is involved with conducting 660 clinical trials across 845 conditions. There are 61 research doctors associated with this hospital, such as Anthony El-Khoueiry, MD, Heinz-Josef Lenz, Jacob Thomas, MD, and Jorge J. Nieva.

Area of expertise

1

Cancer

Global Leader

University of Southern California has run 38 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage III
Stage II
2

Alzheimer's Disease

Global Leader

University of Southern California has run 32 trials for Alzheimer's Disease. Some of their research focus areas include:

APOE4 positive

Top PIs

Clinical Trials running at University of Southern California

Breast Cancer

Lung Cancer

Colorectal Cancer

Cervical Cancer

Cancer

Esophageal Cancer

Squamous Cell Carcinoma

Pancreatic Cancer

Prostate Cancer

Brain Tumor

Image of trial facility.

NX-1607

for Advanced Cancer

This trial is testing NX-1607, a new experimental drug, in adults with advanced cancers that don't respond to standard treatments. The goal is to see if NX-1607 can safely stop or reduce cancer growth, either by itself or with another drug called paclitaxel. Paclitaxel is a widely used anti-cancer drug for treating various types of solid malignant tumors including breast, ovarian, and lung cancers.

Recruiting

1 award

Phase 1

Image of trial facility.

MT-4561

for Cancer

This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors. This study will be conducted in 3 parts. Part 1 is aimed at evaluating safety, tolerability, PK and pharmacodynamics of MT-4561 and determining the Maximum Tolerated Dose (MTD) using the Bayesian Optimal Interval (BOIN) design. The study details and doses of Part 2 (dose-optimization) and Part 3 (Drug-Drug Interaction) will be available after review of applicable Part 1 results.

Recruiting

1 award

Phase 1 & 2

5 criteria

Image of trial facility.

DF1001

for Solid Cancers

This trial is testing a new treatment called DF1001-001 that helps the immune system target and destroy cancer cells. It focuses on patients with certain types of cancers that have a protein called HER2. The treatment works by activating immune cells to recognize and attack these cancer cells.

Recruiting

1 award

Phase 1 & 2

52 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at University of Southern California?

Where is University of Southern California located?

Who should I call to ask about financial aid or insurance network?

What insurance does University of Southern California accept?

What awards or recognition has University of Southern California received?